ORKA — Oruka Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 907654 ·
Last close
$59.06
Market Cap
$3.56B
52W High
$91.00
52W Low
$31.32
ADV30
2,069,744
Next earnings
2026-08-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -36,434,000 | -31,820,000 | 504,480,000 | 49,520,000 | 20,691,000 |
| Dec 2025 | 0 | — | -34,431,000 | -29,583,000 | 488,617,000 | 46,935,000 | 19,618,000 |
| Sep 2025 | 0 | — | -34,105,000 | -30,277,000 | 509,251,000 | 91,253,000 | 22,460,000 |
| Jun 2025 | 0 | — | -28,429,000 | -24,574,000 | 357,418,000 | 65,396,000 | 13,776,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-88,210,000
Investing CF
$-96,745,000
Financing CF
$170,315,000
CapEx
$-209,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.87
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-189,157,000
Inventory
—
Receivables
—
ST Investments
$290,109,000
EBIT TTM
$-105,433,000
Pretax Income TTM
$-105,433,000
Interest Exp TTM
$0
Analysts
12
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -122,051,000 | -105,433,000 | 488,617,000 | 19,618,000 | — | -88,210,000 |
| Dec 2024 | — | — | — | 396,019,000 | 16,729,000 | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.46
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VKTX | Viking Therapeutics, Inc. | $3.58B | $30.80 | — |
| ERAS | Erasca, Inc. | $3.58B | $11.50 | — |
| OGN | Organon & Co. | $3.52B | $13.41 | — |
| EWTX | Edgewise Therapeutics, Inc. | $3.61B | $33.56 | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $3.64B | $21.26 | — |
News headlines (Yahoo Finance, 1h cache)
Oruka Therapeutics (ORKA) Valuation Check After Psoriasis Trial Progress Partnerships And Fresh Funding
2026-05-15 15:18 · Yahoo
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
2026-05-13 21:06 · Yahoo
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company
2026-05-13 20:30 · Yahoo
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally
2026-05-13 20:09 · Yahoo
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-13 20:03 · Yahoo
Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley
2026-05-12 15:54 · Yahoo
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?
2026-05-11 21:35 · Yahoo
H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue Outlook
2026-05-11 20:05 · Yahoo
Leerink Partners Lifts PT on Oruka Therapeutics, Inc. (ORKA)
2026-05-10 23:13 · Yahoo
Why Oruka Therapeutics (ORKA) Is Down 6.3% After $700 Million Follow-On Amid Psoriasis Breakthrough
2026-05-10 18:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.